Curiteva Surpasses More Than 10,000 Levels Successfully Treated
HUNTSVILLE, ALABAMA / ACCESS Newswire / January 21, 2026 / Curiteva, Inc., a privately held, technology and manufacturing company, is...
Year: 2026
Alpha Genesis Announces Research Animal Retirement and Lifetime Care Program to Preserve Animal Welfare, Research Continuity, and National Preparedness
YEMASSEE, SOUTH CAROLINA / ACCESS Newswire / January 21, 2026 / Alpha Genesis Inc., the largest nonhuman primate breeding and...
Alpha Genesis Announces Research Animal Retirement and Lifetime Care Program to Preserve Animal Welfare, Research Continuity, and National Preparedness
YEMASSEE, SOUTH CAROLINA / ACCESS Newswire / January 21, 2026 / Alpha Genesis Inc., the largest nonhuman primate breeding and...
New Year, New Feet: Simple Steps to Healthier Feet in 2026
ATLANTA, GEORGIA / ACCESS Newswire / January 21, 2026 / As people across the country set health goals for the...
New Year, New Feet: Simple Steps to Healthier Feet in 2026
ATLANTA, GEORGIA / ACCESS Newswire / January 21, 2026 / As people across the country set health goals for the...
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
- Single Phase 2/3 Adaptive Study Design -- Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire...
PerfectServe is Furthest in Vision and Highest in Execution in 2026 Gartner® Magic Quadrant™ for Clinical Communication and Collaboration
Marks the company’s third consecutive placement as a Leader following recognition as highest in execution in 2023 and furthest in...
Human Continuum Appoints Dr. Tsun “Sean” Law MD, MBA as its Chief Executive Officer to Lead the Research and Development Efforts Focused on Next-Generation Exosome Therapies and Over-the-Counter Exosome-based Products
Figure 1 Human Continuum Inc. Appoints Dr. Tsun “Sean” Law, MD, MBA as its Chief Executive Officer. New York, N.Y.,...
Ensysce Biosciences Expands Global Opioid Patent Portfolio
~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~ SAN DIEGO, CALIFORNIA / ACCESS...
LiveWorld Announces Human-Led, AI-Powered Strategy & 2026 Solutions Roadmap
Company Unveils Seven AI Solutions for 2026, Built for The New Era of Healthcare MarketingCAMPBELL, Calif. and NEW YORK, Jan....
Aspire Biopharma’s Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
New streamlined, mobile-optimized shopping experience, allows consumers to purchase BUZZ BOMB™ directly, access exclusive promotions and engage with the brand...
The Holy Grail of Cardiology Has Arrived
Peer-Reviewed Paper Confirms Cavadex Drives Plummeting Coronary Artery Calcium Scores : Reversing the Irreversible ROBINA AND QUEENSLAND, AUSTRALIA / ACCESS...
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate...
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for...
ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial
Marc Waldman brings over 35 years of commercial leadership experience in the medical device industry with a proven track record...
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused...
NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts
BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (“NewGen” or the “Company,” NASDAQ: NIVF), a technology-driven company building...
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10...
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613...
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026 LONDON and PHILADELPHIA, Jan....